Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML

被引：0
|
作者：
Zhang, Weiguo [1 ]
Konopleva, Marina [1 ]
Jacamo, Rodrigo O. [1 ]
Borthakur, Gautam
Chen, Wenjing
Cortes, Jorge E.
Ravandi, Farhad
Andreeff, Michael [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
LEUKEMIA;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1495 / 1495
页数：1
相关论文
共 50 条
  • [21] Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
    Schmidt, Franziska
    Erlacher, Miriam
    Niemeyer, Charlotte
    Reinhardt, Dirk
    Klusmann, Jan-Henning
    FRONTIERS IN PEDIATRICS, 2022, 10
  • [22] DNA-PK INHIBITION SENSITIZES FLT3-ITD AML CELLS TO CYTARABINE AND SORAFENIB
    Murray, Heather
    Al Mazi, Juhura
    Kahl, Richard
    Flanagan, Hayley
    Smith, Nathan
    Enjeti, Anoop
    Larsen, Martin
    Verrills, Nicole
    Dun, Matthew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 15 - 16
  • [23] SORAFENIB INDUCED KILLING OF FLT3-ITD AML MEDIATED BY PRO-APOPTOTIC BIM
    Wei, Andrew
    Tan, Peter
    Nguyen, Nhu-Y
    Pomilio, Giovanna
    Teh, Tse-Chieh
    Glaser, Stefan
    Guthridge, Mark
    ANNALS OF HEMATOLOGY, 2013, 92 : S19 - S19
  • [24] Pyruvate Dehydrogenase (PDH) Activity Is a Source of Resistance to Sorafenib in FLT3-ITD Expressing Acute Myeloid Leukemia (AML)
    Anderson, Rebecca G.
    Pladna, Kristin M.
    Pardee, Timothy S.
    BLOOD, 2017, 130
  • [25] Current Approaches to Transplantation for FLT3-ITD AML
    Bradley D. Hunter
    Yi-Bin Chen
    Current Hematologic Malignancy Reports, 2020, 15 : 1 - 8
  • [26] Current Approaches to Transplantation for FLT3-ITD AML
    Hunter, Bradley D.
    Chen, Yi-Bin
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (01) : 1 - 8
  • [27] Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations
    Guenounou, Sarah
    Delabesse, Eric
    Recher, Christian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (06) : 533 - 536
  • [28] Dual Inhibition of AKT/FLT3-ITD by A674563 Overcomes FLT3 Ligand-Induced Drug Resistance in FLT3-ITD positive AML
    Wang, Aoli
    Wu, Hong
    Chen, Cheng
    Hu, Chen
    Qi, Ziping
    Wang, Wenchao
    Yu, Kailin
    Liu, Xiaochuan
    Zou, Fengming
    Zhao, Zheng
    Wu, Jiaxin
    Liu, Juan
    Liu, Feiyang
    Wang, Li
    Stone, Richard M.
    Galinksy, Ilene A.
    Griffin, James D.
    Zhang, Shanchun
    Weisberg, Ellen L.
    Liu, Jing
    Liu, Qingsong
    ONCOTARGET, 2016, 7 (20) : 29131 - 29142
  • [29] Identification of FLT3-ITD mutations in AML patients using different diagnostic methods
    Anta-Szalmas, P.
    Koczok, K.
    Balogh, I.
    Kiss, A.
    Udvardy, M.
    Kappelmayer, J.
    BLOOD REVIEWS, 2007, 21 : S110 - S110
  • [30] FLT3 INHIBITION OVERCOMES RESISTANCE TO THE BCL-2 SELECTIVE ANTAGONIST, VENETOCLAX, IN FLT3-ITD MUTANT AML MODELS
    Sampath, D.
    Mali, R.
    Lasater, E.
    Doyle, K.
    Malla, R.
    Boghaert, E.
    Souers, A.
    Leverson, J.
    HAEMATOLOGICA, 2017, 102 : 42 - 42
12345